Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs

28 Nov 2022

Abstract excerpt

Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate (ADC) that was approved in 2013 to treat HER2+ breast cancer. Despite its efficacy in the clinic, some patients exhibit intrinsic or acquired resistance to such ADC. To characterize mechanisms of resistance to T-DM1, we isolated several HER2+ resistant clones derived from the HCC1954 HER2+ cell line. The isolated clones were different as per their...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Treatment and Pharmacology
Share to HER2/EGFR in Cancer Research
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36455759
DOI: 10.1016/j.canlet.2022.216024

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugsPMID 36455759Read ↗

The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate–resistant HER2-overexpressing breast cancerSemantic proximity Read ↗

Mechanism of action and resistance to Trastuzumab Deruxtecan in patients with metastatic breast cancer: the DAISY trialSemantic proximity Read ↗

Response to trastuzumab-deruxtecan in metastatic triple-negative breast cancer with both HER2 mutation and low expression.Semantic proximity Read ↗

Emerging treatment strategies for HER2-mutant NSCLC: Striving for selectivity, efficacy, and tolerability.Semantic proximity Read ↗

EGFR S442 ectodomain mutation confers cetuximab resistance that can be overcome by ERBB2 blockade with trastuzumab-deruxtecan.Semantic proximity Read ↗

AKR1C mediates the acquired resistance to T-Dxd in a HER-2 positive gastric cancer lineSemantic proximity Read ↗

Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistanceSemantic proximity Read ↗

Effects of Ado-Trastuzumab Emtansine and Fam-Trastuzumab Deruxtecan on Metastatic Breast Cancer Harboring HER2 Amplification and the L755S Mutation.Semantic proximity Read ↗

Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancerSemantic proximity Read ↗

The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistanceSemantic proximity Read ↗

Herceptin resistance database for understanding mechanism of resistance in breast cancer patients.Semantic proximity Read ↗

Genomic mechanisms of resistance to tyrosine kinase inhibitors in HER2 amplified breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.